Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

BACKGROUND: Biomarkers to optimize extended adjuvant endocrine therapy for women with estrogen receptor (ER)–positive breast cancer are limited. The HOXB13/IL17BR (H/I) biomarker predicts recurrence risk in ER-positive, lymph node–negative breast cancer patients. H/I was evaluated in MA.17 trial for...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sgroi, Dennis C., Carney, Erin, Zarrella, Elizabeth, Steffel, Lauren, Binns, Shemeica N., Finkelstein, Dianne M., Szymonifka, Jackie, Bhan, Atul K., Shepherd, Lois E., Zhang, Yi, Schnabel, Catherine A., Erlander, Mark G., Ingle, James N., Porter, Peggy, Muss, Hyman B., Pritchard, Katherine I., Tu, Dongsheng, Rimm, David L., Goss, Paul E.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3888138/
https://ncbi.nlm.nih.gov/pubmed/23812955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt146
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars